Study finds half of agricultural workers with chronic kidney disease in Tamil Nadu have unknown cause

IMT News Desk
IMT News Desk
· 2 min read

A recent study published in The Lancet Regional Health Southeast Asia has found that nearly one in every 20 agricultural workers in Tamil Nadu suffer from chronic kidney disease (CKD). Alarmingly, about half of these cases are attributed to chronic kidney disease of unknown cause (CKDu), which is notably prevalent among farm workers exposed to outdoor working conditions and environmental factors.

The study, conducted across diverse agro-climatic zones of Tamil Nadu with a robust sampling method, evaluated over 3,300 agricultural workers through clinical assessments and laboratory testing. Findings revealed a CKD prevalence rate of 5.31% among this population. Approximately 50% of these cases were CKDu, a condition not linked to typical risk factors like diabetes or hypertension but suspected to be associated with heat stress and exposure to agricultural chemicals or toxins.

Researchers measured kidney function using estimated glomerular filtration rate (eGFR), a key indicator of kidney health. At the end of the first phase, 584 participants showed impaired kidney function, which reduced to 178 in the follow-up phase. Interestingly, 406 participants with reduced eGFR in phase one showed normal values in phase two, suggesting episodes of transient subclinical acute kidney injury (early kidney damage without symptoms) that might contribute to CKD progression.

The study also highlighted a strong correlation between prolonged weekly outdoor work hours and kidney health deterioration. Researchers emphasized that transient acute kidney injury, detected in 17.4% of participants, could significantly increase the risk of developing CKD over time.

This extensive study is the first to cover multiple agricultural zones in Tamil Nadu and offers a clearer estimate of CKD prevalence among agricultural workers, expanding understanding beyond previously studied smaller geographic hotspots.

The findings call for urgent public health interventions, deeper exploration of CKDu causes, and targeted preventive measures to protect vulnerable agricultural communities from this silent epidemic.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk